Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 11, 2008, Pages 3051-3061

  Fatima, Naheed ^a,b   Yi, Ming ^c   Ajaz, Sadia ^e   Stephens, Robert M ^c   Stauffer, Stacey ^a   Greenwald, Peter ^a   Munroe, David J ^d   Ali, Iqbal Unnisa ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Basic Research Laboratory   (United States)

^c Advanced Biomedical Computing Center   (United States)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL METABOLISM; CELL PROLIFERATION; COLORECTAL CANCER; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PYRAZOLES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 55849144744     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0261     Document Type: Article

References (42)

1. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356: 2131-42.
2. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
3. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355: 873-84.
4. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
5. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
6. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-47.
7. Schonthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 2007;97: 1465-8.
8. Kulp SK, Yang YT, Hung CC, et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
9. Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 2005; 113:803-10.
10. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
11. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999- 2007.
12. Shishodia S, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-κB by suppressing activation of IκBα kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 2004;64:5004-12.
13. Fukada K, Takahashi-Yanaga F, Sakoguchi-Okada N, et al. Celecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells. Biochem Biophys Res Commun 2007;357:1166-71.
14. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 2007;73:1318-29.
15. Zhou Y, Ran J, Tang C, et al. Effect of celecoxib on E-cadherin, VEGF, microvessel density and apoptosis in gastric cancer. Cancer Biol Ther 2007;6:269-75.
16. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005;11:8213-21.
17. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005;7:R422-35.
18. Lou J, Fatima N, Xiao Z, et al. Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev 2006;15: 1598-606.
19. Glebov OK, Rodriguez LM, Lynch P, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 2006;15:1382-91.
20. Yi M, Horton JD, Cohen JC, Hobbs HH, Stephens RM. Whole-PathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics 2006;7:30.
21. Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther 2004;3:847-52.
22. Kitagawa R, Kastan MB. The ATM-dependent DNA damage signaling pathway. Cold Spring Harb Symp Quant Biol 2005;70: 99-109.
23. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-42.
24. Ahmed KM, Li JJ. ATM-NF-κB connection as a target for tumor radiosensitization. Curr Cancer Drug Targets 2007;7:335-42.
25. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603.
26. Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signalling in human cancer. Clin Transl Oncol 2007;9:484-93.
27. 2/M transition. Mol Biotechnol 2006;32:227-48.
28. Baldassarre G, Croce CM, Vecchione A. Take your "M" time. Cell Cycle 2007;6:2087-90.
29. Lehmann GM, McCabe MJ, Jr. Arsenite slows S phase progression via inhibition of cdc25Adu al specificity phosphatase gene transcription. Toxicol Sci 2007;99:70-8.
30. Hammer S, To KK, Yoo YG, Koshiji M, Huang LE. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle 2007;6:1919-26.
31. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 2006;18:185-91.
32. Zhan Q. Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat Res 2005;569:133-43.
33. Parrilla-Castellar ER, Arlander SJ, Karnitz L. Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair (Amst) 2004;3:1009-14.
34. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8.
35. Yoshimura T, Matsuyama W, Kamohara H. Discoidin domain receptor 1: a new class of receptor regulating leukocyte-collagen interaction. Immunol Res 2005;31:219-30.
36. Bouckson-Castaing V, Moudjou M, Ferguson DJ, et al. Molecular characterisation of ninein, a new coiled-coil protein of the centrosome. J Cell Sci 1996;109:179-90.
37. Stillwell EE, Zhou J, Joshi HC. Human ninein is a centrosomal autoantigen recognized by CREST patient sera and plays a regulatory role in microtubule nucleation. Cell Cycle 2004;3:923-30.
38. Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematol 2002;108:237-45.
39. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 2007;11:955-65.
40. Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther 2006;5:763-5.
41. Giono LE, Manfredi JJ. Mdm2 plays a positive role as an effector of p53-dependent responses. Cell Cycle 2007;6:2143-7.
42. Irminger-Finger I, Jefford CE. Is there more to BARD1 than BRCA1? Nat Rev Cancer 2006;6:382-91.